Pakistan Faces Medicine Shortages, Counterfeit Risks Due to Pricing Delays
Pakistan is experiencing a critical shortage of over 100 essential medicines, including life-saving drugs for cancer and heart disease, due to prolonged government delays in approving price revisions. The Drug Regulatory Authority of Pakistan (Drap) recommended price adjustments for these "hardship-category" medicines more than two years ago, but the federal cabinet has yet to make a decision. Manufacturers cite rising costs for imported raw materials, energy, packaging, transportation, labor, and currency depreciation, making production commercially unviable under current pricing. Consequently, several pharmaceutical companies have reduced or halted production, exacerbating the scarcity across the country.
Abdul Samad Buddani of the Pakistan Chemists and Druggists Association (PCDA) warned that these shortages are creating a dangerous vacuum, which illegal suppliers and counterfeiters are exploiting. He highlighted that unavailable or critically scarce medicines include oral morphine capsules, streptokinase injections, chemotherapy drugs like cisplatin and doxorubicin, and various immunoglobulin products. Industry representatives are concerned about the integrity of the pharmaceutical supply chain, as desperate patients may resort to unreliable sources for medication, increasing the risk of substandard and counterfeit products entering the market, particularly for expensive and vital treatments. Pharmaceutical manufacturers are urging the government to expedite decisions to ensure the availability of these essential drugs and prevent further supply chain disruptions.
The prolonged delay in adjusting medicine prices in Pakistan, despite recommendations from Drap, highlights a systemic governance challenge. This inaction creates a market void where essential medicines become scarce, directly impacting public health and fostering an environment ripe for illicit markets and counterfeit products. The core issue appears to be a disconnect between the economic realities of pharmaceutical production, driven by global supply chains and currency fluctuations, and the government's pricing mechanisms. This situation forces manufacturers into a position where producing life-saving drugs is financially unsustainable, creating a stark contradiction between the public interest in accessible healthcare and the economic viability of the pharmaceutical industry. Future policy frameworks should consider more agile and responsive pricing mechanisms that balance affordability with the need for manufacturers to maintain production, potentially through indexed pricing or emergency review protocols, to mitigate such recurrent crises and protect citizens from dangerous alternatives.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.